Nagore and colleagues [5] have shown that melanoma patients harboring these specific TERT promoter mutations, in combination with BRAF/NRAS mutations within their tumor tissue, have a significantly shorter disease free survival than patients without this combination. This evidence concerns the gene TERT and melanoma.